Background: In this study, we describe the potential advantages of a continuous-flow total artificial heart (CFTAH) comprising two small, non-pulsatile pumps with optimized responsiveness to the pressure gradient.
Methods: We modified a MicroMed DeBakey axial-flow pump by increasing its inducer-impeller inlet angle, thereby increasing its pressure responsivity. We obtained the in vitro pressure gradient response and compared it with those of the clinically used, unmodified MicroMed DeBakey pump, Jarvik 2000 FlowMaker and HeartMate II.
Results: The modified pump showed an increased response to changes in the pressure gradient at pump flow rates of between 2 and 4 liters/min. The maximum pressure responsivity of the modified pump was 2.5 liters/min/mm Hg; the corresponding maximum responsivities of the Jarvik 2000, HeartMate II and MicroMed DeBakey ventricular assist devices (VADs) were 0.12, 0.09 and 0.38 liters/min/mm Hg, respectively.
Conclusions: Because of the inherent properties of non-pulsatile pumps, the CFTAH may potentially respond to changes in inflow and outflow pressures while maintaining physiologic flow rates sufficient for normal daily activity. In addition, the hemodynamic interplay between the two optimized pumps should allow a physiologic response to normal flow imbalances between the pulmonary and systemic circulations. Improved responsiveness to inflow pressure may further simplify and improve the CFTAH and affect its potential clinical use as a meaningful therapy for terminal heart failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healun.2009.12.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term heart transplant outcomes after lowering fixed pulmonary hypertension using left ventricular assist devices.
Eur J Cardiothorac Surg
December 2018
Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Fixed pulmonary hypertension (fPH) is a challenge for heart transplantation (HTX), but left ventricular assist devices (LVADs) can help reverse it in patients with severe heart failure, allowing them to become candidates for HTX.* -
- This study reviewed 79 patients who received LVADs for terminal heart failure and fPH from 1998 to 2016, finding a significant decrease in pulmonary vascular resistance after LVAD implantation and a median support duration of 288 days before they were eligible for transplant.* -
- Post-transplant outcomes showed similar survival rates between those bridged to HTX with LVADs and a control group, suggesting that LVAD implantation effectively prepares patients with fPH for successful heart transplantation
Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support.
Thromb Res
March 2018
Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA; Department of Biomedical Engineering, Sarver Heart Center, University of Arizona, Tucson, AZ, USA; Department of Medicine, Sarver Heart Center, University of Arizona, Tucson, AZ, USA. Electronic address:
Introduction: Continuous flow ventricular assist devices (cfVADs) continue to be limited by thrombotic complications associated with disruptive flow patterns and supraphysiologic shear stresses. Patients are prescribed complex antiplatelet therapies, which do not fully prevent recurrent thromboembolic events. This is partially due to limited data on antiplatelet efficacy under cfVAD-associated shear conditions.
View Article and Find Full Text PDFArterial pulsatility under phasic left ventricular assist device support.
Biomed Mater Eng
November 2016
Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
The aim of this study is to understand whether the phasic Continuous Flow Left Ventricular Assist Device (CF-LVAD) support would increase the arterial pulsatility. A Micromed DeBakey CF-LVAD was used to apply phasic support in an ex-vivo experimental platform. CF-LVAD was operated over a cardiac cycle by phase-shifting the pulsatile pump control with respect to the heart cycle, in 0.
View Article and Find Full Text PDFRotary Blood Pumps as Long-Term Mechanical Circulatory Support: A Review of a 15-Year Berlin Experience.
Semin Thorac Cardiovasc Surg
March 2017
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany. Electronic address:
This article reports our 15-year single-center experience with rotary blood pumps (RBPs) as long-term mechanical circulatory support (MCS) with emphasis on outcomes. For more than 15-year period, we have used various RBPs as bridge to transplantation or to myocardial recovery. Our group performed the first human implantation worldwide of RBCs, the MicroMed DeBakey ventricular assist device in November 1998 in a patient with end-stage heart failure who was supported for 47 days until his death.
View Article and Find Full Text PDFEnhancement of Arterial Pressure Pulsatility by Controlling Continuous-Flow Left Ventricular Assist Device Flow Rate in Mock Circulatory System.
J Med Biol Eng
June 2016
Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, GEM-Z 4.18, 5600 MB Eindhoven, The Netherlands.
Continuous-flow left ventricular assist devices (CF-LVADs) generally operate at a constant speed, which reduces pulsatility in the arteries and may lead to complications such as functional changes in the vascular system, gastrointestinal bleeding, or both. The purpose of this study is to increase the arterial pulse pressure and pulsatility by controlling the CF-LVAD flow rate. A MicroMed DeBakey pump was used as the CF-LVAD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!